Search
Descriptor English: Aminoglutethimide
Descriptor Spanish: Aminoglutetimida
Descriptor aminoglutetimida
Scope note: Inhibidor de la aromatasa que produce un estado de adrenalectomía "clínica" bloqueando la producción de esteroides adrenales. Asimismo, bloquea la conversión de andrógenos a estrógenos. La aminoglutetimida se ha utilizado en el tratamiento de los cánceres avanzados de mama y próstata. Antiguamente se utilizó como anticonvulsivante suave. (Martindale, The Extra Pharmacopoeia, 30th ed, p454)
Descriptor Portuguese: Aminoglutetimida
Descriptor French: Aminoglutéthimide
Entry term(s): Cytadren
Orimeten
Tree number(s): D03.383.621.808.425.100
RDF Unique Identifier: https://id.nlm.nih.gov/mesh/D000616
Scope note: An aromatase inhibitor that is used in the treatment of advanced BREAST CANCER.
Allowable Qualifiers: AA analogs & derivatives
AD administration & dosage
AE adverse effects
AG agonists
AI antagonists & inhibitors
AN analysis
BL blood
CF cerebrospinal fluid
CH chemistry
CL classification
CS chemical synthesis
EC economics
HI history
IM immunology
IP isolation & purification
ME metabolism
PD pharmacology
PK pharmacokinetics
PO poisoning
RE radiation effects
SD supply & distribution
ST standards
TO toxicity
TU therapeutic use
UR urine
Pharm Action: Antineoplastic Agents, Hormonal
Aromatase Inhibitors
Registry Number: 0O54ZQ14I9
CAS Type 1 Name: 2,6-Piperidinedione, 3-(4-aminophenyl)-3-ethyl-
Public MeSH Note: 73
History Note: 73(66)
DeCS ID: 625
Unique ID: D000616
Documents indexed in the Virtual Health Library (VHL): Click here to access the VHL documents
Date Established: 1973/01/01
Date of Entry: 1999/01/01
Revision Date: 2017/05/24
Aminoglutethimide - Preferred
Concept UI M0000944
Scope note An aromatase inhibitor that is used in the treatment of advanced BREAST CANCER.
Preferred term Aminoglutethimide
Cytadren - Narrower
Concept UI M0000945
Preferred term Cytadren
Entry term(s) Orimeten



We want your feedback on the new DeCS / MeSH website

We invite you to complete a survey that will take no more than 3 minutes.

Go to survey